Trial Profile
Phase II Study Evaluating the Combination of Cetuximab With Afatinib as First-line Treatment for Patients With EGFR Mutated Non Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Aug 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Cetuximab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms ACE; ACE-Lung
- 24 May 2021 Results (n=117) assessing efficacy and toxicity of afatinib+cetuximab versus afatinib alone, in first-line treatment of advanced EGFR-mutant non-small-cell lung cancer, published in the Clinical Cancer Research.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 11 Feb 2019 Planned End Date changed from 1 Jan 2020 to 1 Dec 2020.